Oncology Medical News about metastatic hepatocellular carcinoma;capecitabine and cisplatin;combination chemotherapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma
Annals of Oncology, 06/09/09

Lee JO et al. - In a study to evaluate efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in pts with metastatic hepatocellular carcinoma (HCC). it was shown that based on the observed response rate and time to progression (TTP), XP combination chemotherapy showed modest antitumor efficacy in pts with metastatic HCC as systemic first-line treatment. XP combination chemotherapy showed tolerable toxicity and demonstrated favorable overall survival (OS) time.

Methods

Pts with HCC who had >1 measurable extrahepatic metastatic lesion were enrolled.
Pts received oral capecitabine (2000 mg/m2/day) with a schedule of 2 wks on and 1 wk off and cisplatin (60 mg/m2) on the first day of the 3-wk cycle.

Results

The study cohort consisted of 32 pts with a median age of 53 yrs.
Overall response rate was 6.3% and disease control rate was 34.4%.
Median TTP was 2.0 mos and median OS time was 12.2 mos.
Grade 3/4 hematologic toxic effects included thrombocytopenia (7.6%), neutropenia (4.3%), and anemia (2.1%).
Grade 3/4 non-hematologic toxic effects included elevated hepatic aminotransferase (12.9%), jaundice (3.2%), mucositis (3.2%), and nausea (3.2%).
There was no treatment-related mortality.

<< Previous
Risk factors preventing success of a minilaparotomy approach in...

Next >>
Osteosarcoma of the jaw/craniofacial region